PDCT-13. ENTRECTINIB IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS

The phase 1/2 STARTRK-NG trial is evaluating entrectinib, a CNS-penetrant oral inhibitor of TRK, ROS1 and ALK tyrosine kinases, in children with solid tumors, including primary CNS tumors. Eligible patients are ≤22y with recurrent/refractory solid tumors. The recommended dose was determined in all-c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Robinson, Giles, Desai, Ami, Gauvain, Karen, Basu, Ellen, Dorris, Kathleen, Maese, Luke, Sabnis, Amit, Foster, Jennifer, Shusterman, Suzanne, Yoon, Janet, Weiss, Brian, Abdelbaki, Mohamed, Farid-Kapadia, Mufiza, Meneses-Lorente, Georgina, Cardenas, Alison, Hutchinson, Katherine, Bergthold, Guillaume, Chow Maneval, Edna, Fox, Elizabeth, Gajjar, Amar
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Pediatric Clinical Trials
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847414/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.774
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados